Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.65 USD

85.65
493,550

+2.10 (2.51%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $85.65 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.

Zacks Equity Research

What's in Store for Patterson Companies (PDCO) in Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.

Zacks Equity Research

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Zacks Equity Research

IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?

by Zacks Equity Research

The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.

Zacks Equity Research

Hologic (HOLX) Gains From Core Businesses' Growth, Innovation

by Zacks Equity Research

Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.

Zacks Equity Research

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Zacks Equity Research

Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care

by Zacks Equity Research

Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.

Zacks Equity Research

Cardinal Health (CAH) to Build Distribution Center in Greenville

by Zacks Equity Research

Cardinal Health's (CAH) new facility will be its largest at-Home Solutions distribution center that will support business growth by providing new space and automation.

Zacks Equity Research

CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.

Zacks Equity Research

IDEXX (IDXX) Launches First Veterinary Diagnostic Test

by Zacks Equity Research

IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.

Zacks Equity Research

3 Reasons to Hold Patterson Companies (PDCO) Stock for Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Zacks Equity Research

BD's (BDX) Latest Product to Automate Clinical Flow Cytometry

by Zacks Equity Research

The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.

Zacks Equity Research

Neogen (NEOG) Introduces Improved Genomic Test for Cats

by Zacks Equity Research

Neogen's (NEOG) My CatScan 2.0 offers insightful genetic information that enables preventive cat care by tackling curable conditions.

Zacks Equity Research

Here's Why You Should Invest in Hologic (HOLX) Stock Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.

Zacks Equity Research

Masimo (MASI) Inks Deals for Patient Monitoring Technologies

by Zacks Equity Research

Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.

Zacks Equity Research

NextGen (NXGN) Expands Partnership With Large Urology Group

by Zacks Equity Research

NextGen's (NXGN) cloud-based healthcare technology solution, Enterprise EHR, is selected by Associated Urologists of North Carolina to create an integrated platform, especially for urology-specific workflows.

Zacks Equity Research

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Zacks Equity Research

Encompass Health's (EHC) 158th Hospital Opens in Maryland

by Zacks Equity Research

The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.

Zacks Equity Research

QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center

by Zacks Equity Research

QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.

Zacks Equity Research

Here's Why You Should Retain Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.

Zacks Equity Research

CVS Heath (CVS) MinuteClinic Earns 6th Health Care Approval

by Zacks Equity Research

CVS Heath's (CVS) MinuteClinic has an in-clinic Net Promotor Score of more than 81, putting it in the top customer rankings.

Zacks Equity Research

Revvity (RVTY) Launches Single Solution for Drug Development

by Zacks Equity Research

Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.

Zacks Equity Research

Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.

Zacks Equity Research

Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View

by Zacks Equity Research

Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.